Recovery Kernel

DISCONTINUANCE PROTOCOL: METHAMPHETAMINE

The Crash, the Timeline, and the Road Back to a Working Dopamine System

---

This guide follows the same structure as the Recovery Kernel's Forced Discontinuance series — a safety framework, a genetic cross-reference, a use-pattern classification, a recovery protocol, and a full protocol map — adapted to what methamphetamine discontinuation actually is. It is not a seizure risk the way benzodiazepine withdrawal is. It is, in the Recovery Kernel's own words, 'one of the most profoundly unpleasant biological experiences' a person can go through, and it carries a real and serious risk of its own: the crash produces a depth of depression and anhedonia severe enough to be a genuine suicide risk window. Yeh guide us khatre ko utna hi gambhirta se treat karta hai jitna ki benzo guide seizures ko deta hai.

Section 0 — Immediate Safety: Read This First

⚠ [illegible]

[illegible] [illegible] [illegible] [

The crash itself — extreme exhaustion, hypersomnia, intense hunger, and a wave of depression — is expected and is not, on its own, a medical emergency. It is the body beginning to recover. The distinction that matters is the same one the SSRI guide names: mood and safety, not discomfort. If in doubt, reach out.

Section 1 — Why This Guide Exists

The Recovery Kernel's own meth guide states this plainly: 'something has not gone wrong. Your brain is recalibrating. The misery is the signal that repair is beginning.' That sentence is the organizing idea behind this entire discontinuance protocol. Meth withdrawal has no chemical antidote and no safe substitute-and-taper strategy the way benzodiazepines or opioids do — there is no equivalent of a cross-taper here. What there is instead is a well-documented, predictable biological timeline, and knowing that timeline in advance is itself a form of harm reduction: it is the difference between 'this misery means I need more meth to feeling normal' and 'this misery is Day 3 of a documented process that ends.'

A Brief History: How the Danger Was Discovered

Methamphetamine ko pehli baar ephedrine se 1893 mein Japanese chemist Nagai Nagayoshi ne synthesize kiya tha, aur Akira Ogata ne ise 1919 mein us roop mein crystalize kiya jo aaj bhi pehchana jaa sakta hai. Ise patent kiya gaya aur 1920s mein Japan mein Philopon naam se becha gaya, jiska marketing fatigue, narcolepsy, aur weight loss ke liye kiya jaata tha — ek vaidh pharmaceutical utpaad, jo abhi tak khatarnak samajh nahi aaya tha.

That changed with its mass deployment in World War II. German chemists at Temmler patented their own methamphetamine formulation in 1937, and by 1938 it was being sold over the counter under the brand name Pervitin — distributed to Wehrmacht soldiers in enormous quantities (estimates run into the tens of millions of tablets) specifically to sustain the sleepless, forced-march pace of the Blitzkrieg, and to civilian factory workers to sustain long shifts. Japan ran a parallel program, issuing methamphetamine to kamikaze pilots and to civilian factory workers for the same reason: it let exhausted people keep functioning past the point otherwise their bodies would have stopped them.

□ □□□□□□□□□

□□ □□ □□□□ □□ □□□□□□ 5 □□□ □□□□ □□□□□□ □□ □□□□□□□□ □□□□□□□□ □□ - □□ □□□□□□ □□□□□ □□□ □□ □□□□ □□□□ □□ □□□ □□□□□□□ □□ □□□□□ □□□□□ □□ 1940 □□□ □□□ □□□ □□□□□□□ □□ □□□□□□□ □□ □□□□□□□ □□ □□□ □□ □□, □□ □□ □□ □□□ □□□□□□ □□ □□□

The danger became undeniable in the aftermath. Japan in particular experienced a massive postwar epidemic once wartime military stockpiles were dumped onto the civilian market — by some estimates, a meaningful percentage of the population was misusing the drug within a few years of the war's end. The scale of addiction, psychosis, and physical breakdown this produced was severe enough that Japan enacted the Stimulant Control Law in 1951, one of the first drug-specific stimulant regulations in the world — a direct legislative response to what unrestricted access

had just demonstrated at national scale. What took a global war and □□ □□□□□□□□□ □□□□□□□ □□ 1940 □□ □□□ □□□ □□□□□□□ □□□ □□, □□ □□ □□□□ □□ □□□□□□ 2 □□□□□□□□ □□□ □□□□□□ □□□ □□ □□□□□□ □□□□ □□ □□ □□□□ □□ □□□ □□: □□ □□□ □□ □□□□□□ □□□□□□□□ □□ □□□□□□ □□□□ □□□ □□ □□ □□□ □□ □□□□□□ □□□□ □□ □□ □□□□ □□ □□□□ □□□□ □□□ □□ □□ □□□□□ □□□□□ □□ □□□ □□□ □□□□ □□□

Section 2 — The Withdrawal Timeline

Timeline	What's Happening Biologically	What It Feels Like	What to Do
Hours 0–24 (The Crash)	Dopamine reserves khatam; receptor signalling collapse ho raha hai	□□□□□□□ □□□□, □□□□□□□□□, □□□□□ □□□, □□□□□, □□□□□	Sleep. Khaana khaao. Paani peete raho. Crash se ladna nahi hai — yeh sharir ka theek hona shuru karna hai. Electrolytes.
Days 1–5 (The Pit)	Dopamine on the floor; D2 receptors still downregulated; the system is, in effect, screaming for the chemical it adapted around.	□□□□□ □□□□□, □□□□□□□□□□ (□□□□ □□□□□ □□□□ □□□ □□□□□□□□), □□□□□□□ □□□□, □□□□□ □□□□□, □□□□ □□□ □□□□□□□, □□□□□□□□□□□□□ □□□□□□□□	□□ □□ □□□□ □□□□ □□□ □□□□ □□□□□□ □□□□□□ □□ □□□□ □□ □□□□ □□□□□□ □□□□□□□□□ □□□□□ □□□□ □□□ □□□ □□□ □□□□ □□ □□□ □□ □□□□□ □□ □□□□□ □□□□ □□ □□□□□□ □□□ 9152987821 □□□□□□□ □□□□□ □□□□ 1 □□□□□□□□□ □□□□□□ □□□□ □□□□ (□□□□ 8)□
Days 5–14 (The Gray)	Acute symptoms resolving; dopamine system still significantly impaired; receptor recovery barely beginning	□□□□□□ □□□□ □□□□□ □□□□, □□ □□□□□□□, □□□□□□ □□□□□□□, □□□□□□□□□□□□□ □□□□, □□□-□□□ □□ □□□□□ □□□□□□□	□□□□□ □□□□□□□ □□□□ □□□□ - □□ □□□□□□ □□□□□ □□ (□□□ □)□ □□□□□□□□□□ □□□□□-□□□□□□□□ □□ □□□□□ □□□□ □□ □□□□ □□□□ □□□□ □□□□□
Weeks 2–4 (The Slow Return)	D2 □□□□□□□□ □□□□□ □□□ □□□□□ □□□□□ □□□□□□ □□□□; □□□□□□□□ □□□□□□□□ □□□□-□□□□ □□□ □□□ □□; □□□□□□□□□□ □□□□□□□□□ □□□□□□ □□□□ □□ □□□ □□□	□□□□-□□□□, □□□□□ □□□ □□□ □□□□□; □□□□□□□□□□□□ □□□□ □□ □□□□; □□□□□□□ □□ □□□□□□ □□□□ □□ □□□□ □□□-□□□ □□ □□□□; □□□□ □□ □□□□□ □□□□	Establish a consistent daily routine. The first meaningful behavioural goals become realistic here, not before.
Months 1–3	Measurable D2 receptor recovery;	Genuine improvement with periodic cravings	Identity reconstruction ka kaam yahaan uchit

Timeline	What's Happening Biologically	What It Feels Like	What to Do
	grey matter rebuilding in the prefrontal cortex; dopamine synthesis normalising	and mood variability; post-acute withdrawal (PAWS) episodes possible	ho jaata hai — pehle nahi. Jab asli taur par kshamta wapas aana shuru hoti hai.
Months 3–12	□□□□□□□□□□ □□□□□□□□ □□□□□□; BDNF-□□□□□□□ □□□□□□□□□□□□□□□□□□□ □□ □□□□□□□□□□□ □□□□□□□□ □□□□□□□□□□ □□ □□□□□□ □□□ □□ □□□□□□□□□□□□; □□□□□□□□□□ □□□□□□□□□ □□□□□ □□□ □□□□ □□□□□□	Mood near baseline for most people; cravings are mostly context/cue-triggered rather than spontaneous; cognitive function largely restored; genuine enjoyment of life becomes accessible	Maintain every protocol below. Protect this window from major stress events where possible — the system is rebuilding, not yet at full structural strength.

Section 3 — □□□□□□□□ □□ □□□□□□□ □□□□ □□□ □□□□□ □□□ □□□□□

Yeh sawaal har stage ke timeline ke neeche hai, aur iska seedha jawab chahiye na ki koi dhundli tasalli. Sachcha jawaab do hisson ka hai: acute crisis kuch hafton mein theek ho jaata hai, lekin poora receptor-level recovery kaafi zyada time leta hai — aur yeh jaanna ki asli number kya hai, toh har stage par 'normal' ko kaisa feel karna chahiye, woh badal deta hai.

□ □□□□□□□□□□

The specific data point, cited directly from the neuroimaging research the Recovery Kernel's own material draws on (Volkow et al.): dopamine D2 receptor recovery after methamphetamine cessation is significant, but substantial recovery takes 12 to 17 months of sustained abstinence. This is measurably slower than alcohol (significant D2 receptor improvement by month 1, per Heinz et al.) or cocaine — methamphetamine produces the most extensive dopamine terminal damage of the common stimulants, and the repair timeline reflects that.

□□ □□□ 12-17 □□□□□ □□ □□□ □□□, □□ □□□, □□□□□□ □□□□□ □□□□□□□□□□□□ □□ □□□ □□ □□□□□ □□□□ □□□ □□□□□ □□□ □□□ □□ □□□□□ □□: □□□□ 90 □□□□ □□□□□□ □□□□□□ □□ □□□□□□□□□□□□□□□□□□□ □□□□□□□□□ □□□ □□□□□□□ □□ □□□□□ □□ — □□□ 31 □□ 60 □□ □□ □□□ □□□□ □□ □□ □□ □□□□□□□□ □□□□□ □□□□ □□□□ □□□□ □□□ □□ □□□□□□ □□□□□ □□□□ □□□; □□□ 61 □□ 90 □□ □□ □□□ □□□□ □□ □□ □□ □□ □□□□□□ □□□□□□□□□□ □□□ □□ □□□□□ □□□□□ □□□□□ □□□ □□□□□ □□□□ □□□□ □□□□ □□□□ 90 □□□□□ □□, □□□□□□ □□□□□□□, □□□□, □□ □□□□ □□□□□□ 8 □□□ □□□ □□ □□□□ □□□□□□□□□□□□□□□□□□□ □□□□□□□ □□ □□□, □□□□□□□□ □□□□□□□□ □□□□□ □□□□ □□□□ □□□□ □□, □□□□ □□□□ □□□□□□□ □□□□□ □□□□□ □□□ □□ □□□□ □□, □□ □□□□□□□□□ □□□□□ □□ □□□ □□□□□□□□□□ □□□□□□ □□□ □□ □□ □□ □□□□ □□□ — even though the full 12-17 month recovery is still in progress underneath that.

Recovery Milestone	Realistic Timeline
Acute crash resolves	Days 1–5
Cravings shift from constant to episodic/cue-triggered	Weeks 2–4
First measurable DRD2 receptor recovery on imaging	Weeks 2–4 through Month 1
90-[illegible]	Day 90
Normal mood and cognitive function for most people	Months 3–12
Substantial D2 [illegible]	12–17 months

[illegible]

Agar aap mahine 4 mein hain aur ab bhi bejaan, dhundhle din mehsoos kar rahe hain, toh yeh iska sanket nahi hai ki prakriya fail ho gayi ya ki aap kisi tarah se toote hue hain jiska samay-sarani (timeline) account nahi karta. Upar diye gaye data ke anusaar, aap ek sachmuch abhi recover ho rahe system mein hain — 'near-baseline' mahine 3-12 ka matlab bilkul yahi hai: nazdeek, khatam nahi. Is marammat ki sabse gehri parat (deepest layer) ke liye finish line ek mausam se zyada, saal aur aadhe ke kareeb hai. Yeh koi nirash karne wala number nahi hai. Yeh ek sachcha number hai, aur iska matlab hai ki jo bejaan din aap abhi mehsoos kar rahe hain, woh apekshit hain, na ki kisi nakam hone ka saboot.

[illegible]

[illegible]

Substitute	What It Actually Does to the Recovery Mechanism	[illegible]
Caffeine (used to manage the fatigue and low-motivation phases in Section 2)	Caffeine doesn't deplete dopamine the way methamphetamine does, so it isn't 'the same thing in miniature.' But it does stimulate the HPA axis — adding cortisol-system activation on top of a system, per Section 6, that may already be running hot (especially in the Met/Met 'Worrier' profile) — and heavy or late-day caffeine use directly interferes with sleep quality and duration. Section 8's Tier 3 is explicit that sleep is	Plausibly prolongs the timeline indirectly, by undermining the sleep quality the actual repair work depends on, rather than by any direct dopamine mechanism. The more caffeine is substituted specifically to power through the fatigue Section 2 describes, the more it's

Substitute	What It Actually Does to the Recovery Mechanism	□□□□□□□□ □□□□□□□ □□□□-□□□□ □□
	when BDNF synthesis and dopamine-system repair peak.	fighting the exact process that fatigue is part of.
Alcohol (□□□□ □□ □□□ □□□□□□□□ □□□□ □□□□ □□)	□□ □□□□□ □□□ □□ □□□□ □□□□□□□□ □□□□□□□□□□□ □□□ □□□□ □□□□ □□□□ □□□□ □□, □□□□□ □□ □□□□ □□ □□□□□□ □□ □□□□□ □□□□ □□ □□ □□□□□ □□□ □□ REM □□□□ □□ □□□□□ □□ — □□ REM, □□ □□□□□□□□□□ □□ □□□□ □□□□□□□□ □□ □□□□□□, □□□ □□□□ □□ □□□ □□ □□□□ '□□□□□□□□□□ □□□□□□ □□□□□□□□□□□ □□ □□□□□□□□ □□□□□□□ □□□□□□ □□□□ □□□' □□□□ □□ □□□□□ □□□□ □□□□ □□□□ □□ □□□ □□□□ □□□□ □□ □□□□ □□ □□□ □□ □□□□□ □□□ □□ □□□□ □□□□ □□□□□□□□ □□□□ □□, □□□□□ □□□□ □□□□ □□□□□□ (□□ □□□□ □□ □□□ □□□) □□ □□ □□□□ □□ □□□□ □□ □□□□ □□□□□□ □□□□□□ □□ □□□□□□ □□□ □□ (□□ □□□□ □□ □□□□□□□□ □□□□□□□ □□ □□□□□□ □□□□ □□□□ □□ □□ □□□□□□ □□□ □□□□ □□ □□□ □□)□	Plausibly prolongs the timeline directly, through degraded REM sleep, and introduces a second risk this section's numbers don't account for at all: a new dependence forming on top of the one being recovered from — genuinely likely for the DRD2 A1 allele / Reward Deficiency Syndrome profile in Section 6, where the reward circuit is already primed to over-attach to whatever substance is reliably available.

⚠ □□□□□□□

In dono substitutions ko yahaan moral failure ke roop mein frame nahi kiya gaya hai — caffeine ya drink ki taraf jaana taaki ek bardasht na hone waale samay se guzara ja sake, yeh asli takleef ka bahut samajhdaar jawaab hai. Lekin is guide ka sachcha version saaf taur par kehna padega: in dono mein se koi bhi upar di gayi table mein timeline ke liye neutral bridge nahi hai. Agar neend hi problem hai, toh Section 8 ke Tier 3 mein diye gaye non-alcohol tools (melatonin, magnesium glycinate, glycine, consistent schedule) repair mechanism ke saath kaam kar rahe hain na ki uske khilaaf.

The Fracture: Kyun 'Ek Saal Ka Break, Phir Main Theek Ho Jaunga' Bilkul Sahi Nahi Hai

Ek idea hai jise seedhe address karna zaroori hai, kyunki yeh Section 3 ke apne numbers se nikalne wala ek reasonable-sounding conclusion hai, aur yeh poori tarah galat bhi nahi hai — aur yahi cheez ise khatarnak banati hai. Idea yeh hai: 'agar D2 receptors 12-17 mahine tak kaafi recover ho jaate hain, toh main saal ka break le sakta hoon, apne dimaag ko theek hone deta hoon, aur phir pata laga paunga ki use kaise safe tareeke se karna hai, ya ek clean slate ke saath shuru kar sakta hoon.' Purana addiction-treatment wala framing — 'jaise hi aap dobara uthate hain, turant poori addiction pe wapas chale jaate hain' — yeh 100% sach nahi hai. Lekin yeh instinct ki lambe break se aap zero par reset ho jaoge, woh bhi 100% sach nahi hai. Either. The honest answer lies in the middle, and a fracture is a genuinely useful way to picture why.

What's True (Like a Healed Fracture)	Also True (Why the Gait Still Changed)
The bone does heal. D2 receptor density, per Section 3's data, does genuinely recover on a real, measured timeline — this is not a euphemism or a hopeful story, it's what the imaging shows.	Ek jura hua haddi, na tooti hui haddi ke barabar nahi hota. Yeh chot ke aas-paas khud ko naya banata hai. Yeh phir se asli wazan utha sakta hai — lekin automatically utna load, usi angle par, usi tarike se, bina is baat ko dobara seekhne ki zaroorat ke ki body kaise kaam karti hai.
Tolerance is genuinely lost during real abstinence — this is well-documented pharmacology, not guesswork.	[illegible]
[illegible]	Yeh bina kisi aadhaar ke nahi hai. Section 6 ka epigenetic material batata hai ki reward-circuitry gene expression kaise baar-baar istemaal se badalta hai — aur un badle hue pathways ko dobara activate karne ke liye zaroori nahi hai ki woh bilkul shunya se banaye jaayen. Ek pehle se bane raaste par phir se chalna, usse zyada tez ho sakta hai ki jitni speed se pehli baar naya raasta banta hai. Isi wajah se break ke baad relapse aksar utna tezi se badhta hai jitna original istemaal mein hua tha, bhale hi baseline receptor measures sach mein recover ho gaye hon.

⚠ [illegible]

To put it plainly: a period of real abstinence is not a reset button, and it's not useless either — both of the framings the introduction to this section named are partly right and partly wrong at the same time. What it actually produces is a system that has repaired in the ways Section 3 describes, while remaining structurally different from the one that existed before use ever started — different tolerance, different vulnerability to fast reactivation, different cardiovascular capacity. Trying to put the exact same weight on it, the exact same way, is where the danger concentrates. This isn't a technical Note. It's the reason relapse after a real break carries its own distinct, elevated risk profile rather than being either 'safe now' or 'instantly back to square one.'

A Popular Claim Worth Correcting: 'Your Cells Fully Replace Every 7 Years'

Yeh idea bahut jagah chalta hai, khaaskar recovery communities ke andar bhi — lekin yeh us cheez se match nahi karta jo asal mein measure kiya gaya hai, aur sahi version myth se zyada upyogi hai, kam nahi. Alag-alag tissues alag-alag speed se change hote hain: skin aur gut lining kuch dinon se hafton mein, fat cells saal ka lagbhag 10% hissa, skeleton ek dashak (decade) mein. Lekin woh tissue jo is guide ke sabse zyada important hai — cerebral cortex ke neurons — vikas ke shuruati daur ke baad bilkul bhi meaningfully replace nahi hote hain. Reward pathways mein shaamil neurons jiske baare mein yeh poora guide bata raha hai, to a large extent, the same physical cells you had before you ever used methamphetamine. They are not swapped out for fresh ones on any timeline, seven years or otherwise.

□□ □□□□ □□ □□□ □□ □□□□? □□ □□□□□□□□ □□□□□, □□□□ □□ □□□□ □□□□, □□ □□□□ □□□ □□□□□□□□ □□ □□ □□□ □□ □□□□□ □□□□ □□, □□ □□□□□□ □□□□□ □□ □□□□□ □□□□ □□ □□□□□ □□□□ □□□ — □□ □□□□ □□ □□□□□ □□□□□□□□□ □□ □□□□□□□□□□ □□ □□□□□, □□□□□□□□□□□ □□ □□□□□□□□□□ □□, □□□ □□ □□□□ □□□ □□ □□□□□□□□□ □□□□□□□ (□□□□□□ 6 □□ □□□□□□□□□□□□□ □□□□□□□)□ □□□□□, □□□□ □□□□□□ □□□ □□ □□□□ □□□ □□□□□ □□, □□ □□□ □□ □□□□□ □□□ □□ □□□□□□□□□□ □□□□□ □□ □□□□□□ □□: □□□□□□ □□□□□□□□□ □□□□-□□□□ □□□□ □□□□ □□□□ □□, □□□ □□□□□ — □□□□□□ □□□□□ □□□ □□□□□ □□□□□□ □□□□□ □□ □□□□□ □□□ — □□□□□□□ □□□□ □□□ □□ □□□□ □□□ □□□□□ □□□□□□ □□□ □□ □□□□□□ □□□□ □□□, □□ □□□□ □□□□ □□□□□□□□□□ □□□ □□□□□□□ □□□□ □□□ □□ □□□ □□ □□□ □□□ □□□□ □□□□ □□□□ aur background neuroinflammation mein yogdaan karta hai. Yeh asli baat hai, vartamaan addiction aur aging science ki baat hai, aur iska matlab hai ki recover hota system koi fixed target nahi hai — yeh repair karte samay hi background mein age bhi raha hai, jisse poori prakriya ko mushkil ya dheema mehsoos ho sakta hai jitna zyada samay aur jitna zyada jama hua istemaal beet chuka hai, Section 3 mein dopamine-specific timeline se aazad.

□□□□□

because the same neurons persist rather than getting replaced, the old pathways this guide has discussed — the fast reactivation risk, the learned cue responses — are not gone after a year off. They're still physically present, in the same cells, just quieter. That is exactly why writing off a year of real work as 'it didn't work' or 'I wasn't strong enough' or reaching for 'once an addict, always an addict' is the wrong conclusion to draw from a relapse — but so is assuming a year was ever going to erase pathways that were never going to be deleted in the first place, only outcompeted. The actual task was never full erasure. It's building new, competing pathways strong enough that the old ones stop being the path of least resistance — which is precisely why Section 11's Protocol 20/C-28 material talks about redirecting this exact reward circuitry toward genuine, high-intensity natural alternatives, rather than asking the circuitry itself to disappear. And it's worth saying plainly: returning to a substance after time away is not always someone deciding they could 'get away with it.' □□□□□□ □□□□□□ □□□□□□□□ — □□□□□, □□□□□, □□ □□□□ □□□ □□ □□ □□□□□ □□□ □□□□ □□□□ □□□ □□□□□ □□ □□ □□□□□ □□□ □□□□ □□□ — □□ □□□□ □□ □□□ □□ □□□□□□□□ □□ □□□ □□□ □□□ □□□□ □□□□□□ □□, □□□□□ □□□ □□□□□□□□□□ □□ □□□□□ □□□□□□ □□ □□□ □□□□□ □□□□□ □□ □□□□□ □□□□ □□□

Section 4 — □□ □□□□ □□□□ □□□□ □□□□□ □□□□□□

Section 2 ka timeline aapko bataata hai ki jaivik roop se kya ho raha hai aur lagbhag kab. Yeh section alag hai — yeh koshish karta hai ki andar se mehsoos karne wali cheez ko bataye, table row jitna zyada gehraai mein, taaki jab woh ho toh aap use pehchaan lein na ki us par ghabraein.

Anhedonia — sabse mushkil lakshan ke liye sabse halka shabd.

Anhedonia gets mentioned almost clinically in most withdrawal material — 'inability to feel pleasure' — as if that fully captures it. It doesn't. What it actually feels like, for most people, is closer to watching your own life through glass: food doesn't taste like much, music you used to love registers as sound without the feeling attached, a joke lands as information rather than something funny, a person you love doesn't produce the warmth being near them used to produce. It is not that you've stopped caring. It's that the machinery that used to translate 'good thing happening' into 'felt good' is running at a fraction of its normal signal, because that machinery is the exact dopamine system methamphetamine hijacked and depleted. This is genuinely one of the most disorienting parts of the entire process, because it can produce a second-order fear on top of the flatness itself — 'what if I never feel anything again' — and that fear is worth naming directly: per Section 3's data, this is a documented, temporary state with a known recovery arc, not a permanent personality change.

Other symptoms worth naming plainly

- Hypervigilance aur ek tez, bechain tarah ki feeling, thakaan ke bawajood bhi —nervous system utna jaldi slow nahi hota jitni body ko neend chahiye hoti hai.
- Intense, specific cravings that arrive with almost no warning, often triggered by something completely mundane — a smell, a piece of music, a text notification — and that can feel, in the moment, like the only thing that will make the current state bearable.
- Chidchidapan aur chhota swabhav jo aapko aur aas-paas ke logon ko achanak se jhatka de sakta hai, khaaskar Pit phase mein (Din 1-5).
- Actual cognitive fog—word-finding difficulty, trouble following conversations, a feeling like thinking through mud. This is not a sign of permanent damage; it follows the same recovery arc as everything else in Section 2 and 3.
- Vivid, kabhi-kabhi pareshan karne wale sapne jab neend aana shuru hoti hai —yeh dimag ek lambe samay tak dabey ya tukde-tukde neend ke baad bahut saara catch-up REM processing kar raha hota hai.

Yeh ek aisa point hai jise zyada dhyaan se dekhna chahiye, kyunki yeh aksar sabse zyada pareshan karne waale symptoms ki jagah sabse zyada confusing hota hai. Wahi BDNF-driven synaptic strengthening jo dopamine system ko repair kar raha hai (Section 3), woh partly glutamate signalling ke through kaam karta hai — glutamate aur NMDA receptor activity synapses ke actually strong hone ka ek normal, zaroori hissa hain, na ki sirf ek toxic byproduct. Toh is recovery window mein badhi hui dream activity ko dual causation ke roop mein samajhna sabse

accha hai: asli repair work ho raha hai, jiske side effect ke taur par unusually vivid aur frequent dreaming ho raha hai, yeh primarily ongoing damage ka sign nahi hai. some people this goes further than just vivid — dreaming intensely enough to physically wake up from it, sometimes repeatedly through the night, which becomes its own sleep-disruption problem layered on top of the insomnia already present. Others notice they're suddenly recalling dreams in detail they normally wouldn't — waking up and being able to describe a dream at length, sometimes catching themselves talking about it as though it were something that actually happened, before the distinction settles back in. Both of these are consistent with the REM rebound and synaptic remodeling happening during this window, not signs that something has gone wrong with your grip on reality.

□□□□□

Agar aap upar di gayi anhedonia ka vivaran padh kar yeh sochte hain ki 'yahi hai, aur mere paas iske liye koi shabd nahi tha' — toh yeh pratikriya aam hai, aur is par rukna zaroori hai. Bahut se log is khaas lakshan se guzarte hain, jismein unhein lagta hai ki unmein kuch alag galat hai, khaaskar isliye kyunki kisi ne ise itne vistar se varnan nahi kiya ki woh ise ek jaani-maani, dastavezi cheez ke roop mein pehchaan sake jo lagbhag sabhi logon ko hoti hai jo isse guzar rahe hain. Iska ek naam hai. Iska ek samay-chakra hai. Yeh aap nahin hain.

□□□□ □□□ □□ □□□□□□□ □□□□□ □□: □□□□□□□□ □□□ □□□□□ □□ □□□□ □□□□□

□□ □□□□□□ □□ □□□□□ □□ □□□ □□□□, □□ □□□□ □□ □□□ □□□ □□□□ — □□□□□□ 2 □□ □□□□□□ 3 □□ □□□□□□□□ □□□□ □□ □□ □□ □□□□□□□□ □□□ □□□□□ □□ □□□□□ □□□□□ □□ □□□□ □□□□□□ □□□□□ □□□ □□ □□□ □□□□□□□ □□□ □□ □□□□□□□□ □□□□ □□ □□□ □□□□ □□, □□ □□□□□□□□□□□ □□□□□□ □□□□□□□□□□ □□□ □□□□ □□ — □□□□□ □□ □□□□□□□, □□□□ □□ □□□□ □□□□ □□□□ □□□ □□ □□□□ □□ □□ □□□□□□□ □□□□□ □□ □□□□ □□ □□□ □□ □□□□ □□□ □□□□ □□□□ □□□□□ □□□□□□□□□□ □□ □□ □□□□ □□□ □□ □□, □□□□□□□ '□□ □□□□□ □□□□ □□□ □□□□□□□ □□□□□ □□□□ □□□□/□□□□/□□□□ □□□□ □□□□ □□' □□ '□□ □□□□□□ □□□ □□□□ □□ □□□ □□' □□□ □□□□ □□□□ □□, □□□□ □□□□ □□□□ □□□□□ □□□□ □□□□□□ □□□ □□□□ □□ □□□□ □□□□ □□□□ □□□

What Makes It Worse	Why
□□□□ □□□□ □□ □□□□ □□□□□□□□□□ □□□□□ □□□□□□	Blood sugar spikes aur crashes se mood ki instability aur energy crashes aur badh jaate hain jo dopamine ki kami se ho rahe hain — ek crash ke upar ek crash.
Caffeine aur sharab	Section 3 mein poori tarah se cover kiya gaya hai — caffeine anishchit roop se, neend mein rukavat aur HPA-axis ko uttejit karne ke zariye; alcohol seedhe taur par, REM ki kami ke through jo pehle se ho rahi REM rebound ke upar.
Nicotine aur anya stimulant	The obvious one, but worth stating plainly: any stimulant, including nicotine, keeps the same reward and arousal circuitry engaged that this entire recovery is trying to let settle.
□□□□ □□□□ □□ □□□□□ - □□□ □□□ □□ □□□□□□□ □□□□□, □□□□□□□	□□□□ □□□ □□ □□□□ □□ □□□□□□ □□□□□□ □□□□□ (BDNF □□□□□□□□, □□□□□□ □□□□□) □□ □□□□□ □□□□ □□ □□□□ □□□□ 8

What Makes It Worse	Why
[illegible]	[illegible]
Dehydration aur khana chhod dena	The brain doing this much repair work needs consistent glucose and hydration; running on empty adds a second, unnecessary layer of depletion on top of the biological one already happening.
[illegible]	Naa khaana ya padarth nahi, par yahaan shaamil karna uchit hai — alag rehna isse saabit roop se bigadta hai har withdrawal syndrome jiska yeh library dastavezi karta hai, aur yeh support contact ko hata deta hai jise Section 0 sabse zyada khatre wale samay mein surakshit maanta hai.

[illegible]

Exercise is the clear exception to this list, and deserves to be named as one rather than lumped in with caution about overdoing things. Per Section 8's Tier 3, it is the primary mechanism generating the BDNF that drives the entire recovery timeline in Section 3 — more of it, not less, is the general direction to move in as capacity allows.

[illegible]

Here's the part worth saying directly: almost everything painful in this recovery — the flatness, the fatigue, the intense dreams, the cravings — is your body actively repairing itself. It is not a sign that something is wrong. It's easy, in the middle of it, to mistake the discomfort of repair for evidence that recovery isn't working, and to reach for the drug specifically to make an idiopathic-feeling wave of symptoms stop — not because the craving itself got stronger, but because nobody told you that what you were feeling was expected, temporary, and productive. Knowing that in advance doesn't [illegible]

Section 5 — The Work-Driven Use Pattern and the Dream-Wake Overlap

Not everyone who develops methamphetamine dependence started from a party or a crisis. A real and common pattern is use that began, or escalated, specifically to work — long shifts, multiple jobs, caregiving on top of a full workday, the kind of chronic overextension where stopping doesn't feel like an option. Methamphetamine's stimulant effect can look, for a while, like the only way to keep meeting a schedule that was never sustainable to begin with. This pattern deserves its own mention because it produces a specific and distinct symptom that other descriptions of meth use often miss entirely.

⚠ [illegible]

[illegible]

□□□□□ □□□ □□□□□□ □□□□ □□□□ □□ □□□□ □□: □□ □□ □□□□□□ □□□ □□ □□□□ □□□□ □□□ □□ □□□□□□□□□, □□□□□, □□□□□□□□ □□□□□□ □□ □□□□□□□□□, □□□□□□□□□□□ □□ □□□□□, □□ □□□ □□ □□□□ □□□□ □□□ □□ □□□ □□□□ □□ □□□□ □□ □□□ □□□ □□ □□□□ □□□□ □□□□□ □□ □□□□□ □□□□□ □□□□ □□ □□□ □□ □□ □□-□□□□□□□□□ □□□□□□ □□ (□□□-□□□ □□□□□□□□□□□ □□□□□□□□ □□ □□□□□□ □□□□□□□ □□ □□□ □□□□□□□□□□□□ □□□ □□□□ □□), □ □□ □□□□□□□□□ □□ □□□□□ - □□□□□□□ □□□□□ □□□ □□□□□□□□ □□□ The psychosis risk mentioned in Section 0, and any variation of this that involves paranoid delusions or a break from reality testing (instead of brief, dream-like perceptual intrusions), should be assessed as described in Section 0.

Agar yeh pattern aap par lagu hota hai, toh recovery task mein kuch aisa shaamil hai jiska baaki guide poori tarah se cover nahi karta: sirf substance ko nahi, balki uske neeche ke overwork ko asal mein theek karna. Dopamine system ko rebuild karna (Section 3) aur saath hi usi unsustainable schedule par wapas jaana jisne pehle dependence create karne mein madad ki thi, yeh toh tootne waali conditions mein dobara build karna hai. Yeh sachai se naam dena zaroori hai na ki isse chhod ke rehna.

Section 6 — Genetic Cross-Reference

Gene	What It Governs	Relevance Here
COMT (Val158Met)	Dopamine clearance speed	Val/Val ('□□□□□□', □□□□ □□ □□□□□□□) □□□□□□□□□□□□□□□ □□ □□□ □□□□□□□□□ □□□□□□□ □□□□□□□□□□ □□ - □□ □□ □□□□ □□ □□□□ □□□□ □□□□, □□□□□□□ □□□□□ □□□□ □□□□□□□ □□ □□ □□□ □□ □□□□□□□ □□□□□□□□ □□□□□ □□□ □□□ □□□□ □□ □□□□□ □□□□ □□□ □□□ □□□□ □□□ □□□□□□□ □□□□□ □□□□□□ □□ □□□ □□□□□□□□ □□□□-□□□□□□□ □□□□ □□□□□□ □□□□□, □ □□ □□□□ □□□□□
DRD2 / ANKK1 (Taq1A, A1 allele)	DRD2 receptor density	A1 allele carrier ka reward circuit kam baseline D2 density ke saath chalta hai — Reward Deficiency Syndrome. Yeh recovery supplementation ke liye sabse zaroori genetic target hai (Section 8 mein 'Brain Stack'), kyunki receptor system ko khud density rebuild karne ki zaroorat hai, sirf drug clear karne ki nahi.
MAOA (uVNTR)	Dopamine, serotonin, and norepinephrine are neurotransmitters that play crucial roles in regulating mood, arousal, attention, and motivation. While they all function as chemical messengers in the brain,	□□ □□□□□□ □□□□ □□□□□□□□ □□□ □□□□ □□□□ □□□; □□□□ □□□□□□ □□□□ □□□□□□ □□□□ □□ □□ □□ □□□□ □□□□ □□□□□ □□□□□□ □□□□ □□□□□□□□□ □□ □□□□□ □□ □□□□□□□ □□ □□□□ □□ - □□ □□□□□□□□□ □□ □□□ □□ □□□□□□ □□ □□□□ □□ □□□□□ □□ □□□□ □□□ □□□□□□□□ □□□□□ □□ □□□ □□□□□□□□□ □□□

Gene	What It Governs	Relevance Here
	their breakdown mechanisms and associated enzymes differ to varying degrees. Here is a general overview of their metabolism: **1. Dopamine (DA)** * **Primary Breakdown Enzyme:** Monoamine Oxidase (MAO) and Catechol-O-Methyltransferase (COMT). * **Mechanism:** Dopamine is primarily broken down by MAO, particularly MAO-A in the brain. COMT also plays a role, especially in peripheral tissues. * **Inhibition:** Medications that inhibit these enzymes (MAOIs or COMT inhibitors) are used clinically to increase dopamine levels. **2. Serotonin (5-HT)** * **Primary Breakdown Enzyme:** Monoamine Oxidase (MAO). * **Mechanism:** Serotonin is mainly cleared from the synaptic cleft by reuptake transporters, but its breakdown involves MAO. * **Inhibition:** Selective Serotonin Reuptake Inhibitors (SSRIs) block the reuptake mechanism, increasing serotonin concentration in the synapse.	

Gene	What It Governs	Relevance Here
	3. Norepinephrine (NE) * **Primary Breakdown Enzyme:** Monoamine Oxidase (MAO) and Catechol-O-Methyltransferase (COMT). * **Mechanism:** Like dopamine, NE is subject to breakdown by MAO. COMT also contributes to its metabolism. * **Inhibition:** Medications that block the reuptake of NE or inhibit its breakdown are used to boost its levels. **Summary Table** | Neurotransmitter | Key Breakdown Enzymes | Primary Clearance Mechanism | | :--- | :--- | :--- | | Dopamine (DA) | MAO, COMT | Reuptake, Enzymatic Degradation | | Serotonin (5-HT) | MAO | Reuptake, Enzymatic Degradation | | Norepinephrine (NE) | MAO, COMT | Reuptake, Enzymatic Degradation | *Note: This is a simplified overview. The actual regulation involves complex interplay between transporters, enzymes, and receptor activity.*	
BDNF (Val66Met)	[illegible]	Met carriers [illegible] [illegible] [illegible] BDNF [illegible] [illegible] [illegible]-[illegible] BDNF [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] [illegible] - [illegible] [illegible] [illegible] [illegible]

Gene	What It Governs	Relevance Here
		[illegible] Met [illegible] [illegible] [illegible]

dimag ki primary inhibitory ('braking') system ki density aur sensitivity ko govern karta hai — jo impulse, urge, aur behaviour par brakes lagane ki general capacity hai jab woh pehle hi chal pada ho. Yeh seedhe taur par is baat se sambandhit hai ki kisi khaas vyakti ke liye 'bas ruk jaana' kitna mushkil hai, willpower se alag hokar.

GABRA2 Profile	What It Means for Stopping
Lower-risk / typical GABRA2 function	[illegible]
High-risk GABRA2 variant (thinner baseline inhibitory tone)	Less braking capacity available before use ever starts — meaning the gap between craving and action is genuinely shorter and harder to widen through willpower alone. This is a hardware difference, not a character difference, and it's the same GABRA2 architecture documented in the Recovery Kernel's GABA Braking Systems material for benzodiazepines and alcohol — it applies here too, just to impulse control generally rather than to a GABA-A drug specifically.

SANCTUARY

Agar aapko lag raha hai ki band hona unse zyada mushkil hai jisse aap jaante hain aur jo same drug, same amount use karte the — toh woh farak asal hardware ka ho sakta hai, na ki koshish ya commitment mein kami ka. GABRA2 status bilkul us tarah ki cheez hai jo 'bas band kar do' ko do alag nervous systems ke liye ek bahut hi alag kaam bana deti hai jab unhe ek jaisa craving face karna padta hai.

Genes Se Zyada: Kya Meth Ka Istemal Gene Expression Badalta Hai?

Table mein upar di gayi sab cheezein us genetic hardware se judi hain jo kisi ko paida hote waqt milta hai. Ek alag aur tezi se padha ja raha sawaal yeh hai ki kya methamphetamine ka istemaal khud genes ke expression (vyaktitva) ko badalta hai — underlying DNA sequence ko nahi, jise use alter nahin karta, balki epigenetic marks ko jo determine karte hain ki kaunse genes on ya off hote hain, aur kitni taakat se. Yeh antar mahatvapurna hai: kisi bhi insaan ka genetic code istemaal karne se rewrite nahin hota, lekin khaas genes ki activity level — vishesh roop se dopamine-pathway aur stress-response genes jo is section mein discuss kiye gaye hain — sustained use ke saath sachmuch badal sakti hai.

What's well-established in addiction neuroscience broadly (this is not meth-specific research alone, but methamphetamine is included in the broader literature it's drawn from): repeated stimulant exposure drives the accumulation of a transcription factor called ΔFosB in the brain's reward circuitry, which in turn alters the expression of a range of downstream genes involved in reward sensitivity and craving — this is one of the most replicated findings in addiction molecular biology, described in the foundational literature this compendium's own bibliography cites (Nestler, 2001, on the molecular basis of long-term plasticity underlying addiction). Whether methamphetamine produces additional, drug-specific epigenetic signatures beyond [illegible]

[illegible] [illegible] [illegible] — [illegible] [illegible] [illegible]

□□□ □□□□ □□□□ □□ □□□□ □□□ □□ □□□, □□□□ □□□□□□□

Full genetic testing (COMT rs4680, DRD2/ANKK1 Taq1A) is the most precise way to know, but it isn't accessible to everyone, and the more urgent and available screening tool is a plain history — this is worth going through honestly, ideally before any use, or as early as possible into recognizing a use pattern:

- □□□□ □□□□ □□□□-□□□□, □□□-□□□ □□ □□□□-□□□□ □□□ □□□□□□□□□□□□□□□□,
  □□□□□□□□□□ □□□□□ (bipolar disorder), □□ □□□□ □□ □□□□□□ □□ □□□□□□□□□□
  □□□□□□ (psychotic episode) □□ □□□□□□□□□□ □□□□□□ □□?
- Kya aapne vyaktigat roop se kabhi koi anubhav kiya hai, kisi bhi padarth par shaamil hokar, jismein sirf bahut alag mehsoos nahi hua, balki yeh kho diya ki asal mein kya real hai—sirf paranoid ya anxious nahi, balki sach mein anishchit ki aapke aas-paas kya ho raha hai?
- Kya aap bina kisi substance ke bhi aam star ke uttejana se vyast, chintit ya atyuttejit ho jaate hain—jo ki upar diye gaye Section 6 mein varnit Met/Met 'Worrier' pattern hai?
- Kya kisi psychiatrist ya doctor ne kabhi mood ya psychotic-spectrum disorder ki sambhavna uthai hai, bhale hi aapne us par zyada baat na ki ho ya sehmat na hon?

⚠ □□□□□□□□

Any combination of a 'yes' on the family or personal history questions with the Met/Met stimulant-sensitivity pattern is worth treating as a genuine contraindication, not a risk factor to weigh against the appeal of the drug's effects. This is the one place in this entire guide where the message isn't 'here's how to reduce the danger' — it's 'this specific combination is why the danger can't be fully reduced.' If this describes you or someone you're trying to help, a psychiatric evaluation before any further use — not after a crisis — is the responsible next step, and it's a A completely reasonable thing to discuss with the doctor directly would be, "I want to understand my personal psychosis risk before I use this again."

Phenotyping Without Test Results

- □□□□ □□□□□□□ □□□□□□□□ □□ □□□□ □□□□□□□, □□□□□□□□ □□ □□□□□ □□□□□ □□□□□ □□ □□□□ □□ □□□□ □□ □□□ □□□□ □□□? $\rightarrow$ □□□□□□ □□□□□□ COMT □□□□□□□□ □□ □□□ □□ DRD2 □□ □□□□
- Kya aapne kisi khaas cheez ko karne ke liye stimulants ka istemaal kiya—zyada mehnat karna, zyada der tak kaam karna, aur zyada paana? → Shayad Val/Val COMT.
- Kya aapne kisi prescription stimulant se shuru kiya aur usse badha (escalate) kiya? → Sambhavatah ek DRD2 kami hai jiske saath tolerance viksit ho gaya hai.
- Kya aap bina istemaal kiye bhi depression ya bhavnatmak nirasha se jujhte hain? → Sambhavatah MTHFR mein sankraman hai — Methylation support (5-MTHF), Section 8 mein sab kuch ke saath ek prathmikta hai.

Section 7 — Use Pattern Classification

Pattern	Typical Profile	Withdrawal Severity	Recommended Posture
Low	Kabhi kabhi, binge nahi karne ke liye istemaal karna; munh se ya kabhi kabhi chhoos kar; kul kuch hafton mein istemaal karna	Lower — crash is real but typically brief and less severe	Cessation karna akela bhi surakshit hai, lekin mood girne ke kaaran ek support contact ab bhi faydemand rahega. Section 0 ke safety signs abhi bhi lagu hote hain.
Medium	Regular use, not in extended binges; weeks to a few months of use	Moderate — section 2 ke timeline mein poora crash aur pit phase expect karna.	A support structure and the Section 8 supplement stack from day one meaningfully reduce severity.
High	Binge-crash cycling — multi-day use periods followed by extended crashes — for months	High — the binge-crash pattern itself accelerates dopamine system depletion beyond what steady use produces	[illegible]
Chronic / IV or smoked route, long-term	Months to years of use, especially via smoking or injection (faster, more intense dopamine spikes and correspondingly deeper depletion)	Highest — yeh woh aabadi hai jismein Section 3 mein 12–17 mahine ka D2 recovery timeline maapa gaya tha	Acute crash ke dauraan poora medical aur psychiatric sahayata prapt karna bahut zyada salah di jaati hai. Yeh woh janta bhi hai jo sirf khud se kiye jaane wale protocol ke bajaye, formal ilaaj mein shaamil hone se sabse zyada fayda utha sakti hai.

Section 8 — The Recovery Protocol

⚠ □□□□□□□□

Yahaan kuch bhi khudkushi ke vicharon, psychosis, ya cardiac event ka ilaaj nahi karta hai. Agar koi Section 0 sign maujood hai, toh woh is protocol se zyada mahatvapurna hoga.

Tier 1 — □□□□□ □□□□□

Two additions below speak directly to the glutamate side of this recovery, alongside NAC — meth's dopamine surge co-releases glutamate in cortico-striatal circuits, and excess NMDA receptor activation from that glutamate is a real contributor to the neurotoxicity in Section 3, and plausibly to the intensified, sometimes disturbing dreams that show up as REM sleep rebounds once real sleep returns (Section 4).

Support	Role
Tyrosine (500-1000mg, subah, protein se door)	Dopamine precursor — start once eating regularly, usually on Day 3-5.
NAC (600mg twice daily with food)	Dual-action: glutamate homeostasis aur craving reduction via cystine-glutamate exchange system, aur ek glutathione precursor jo liver detoxification ko support karta hai — chronic meth use, khaaskar jab kisi bhi adulterants ke saath supply mein ho, hepatic detox pathways par asli bojh dalta hai, aur NAC liver ke primary antioxidant molecule ko replenish karta hai.
NAD+ (□□□□□□□□□□□□ □□□□□□ □□□□□□□□□□□□□□□□□□)	Chronic substance use significantly depletes NAD+, a coenzyme central to cellular energy production and DNA repair — part of why early recovery involves such profound fatigue. IV infusion is the most effective and most studied delivery route for acute withdrawal support specifically, with some clinical programs reporting meaningful reduction in withdrawal discomfort; nasal spray, sublingual, and oral precursor (NMN/NR) forms are more accessible but less direct. This is a genuine option, not a first-line necessity — the foundational work below (sleep, exercise, nutrition) accounts for the large majority of physiological recovery; NAD+ and other advanced interventions are a real but a smaller addition on top of that foundation, not a substitute for it.
□□□□□□□□ □□-□□□□□□□□□ (□□□□□ 200-400 □□□□□□□□□)	A complement to NAC's role above, working on a different part of liver detoxification: it inhibits beta-glucuronidase, an enzyme that can reverse the liver's Phase II conjugation process and let already-packaged toxins and hormone metabolites get reabsorbed back into circulation instead of properly excreted. Where NAC supports the glutathione conjugation pathway directly, calcium D-glucarate helps make sure what the liver has

Support	Role
	already processed actually leaves rather than recirculating — relevant background support during a period when the liver is managing both the substance itself and whatever adulterants were in the supply.
□□□□□□□□□□ □□□□□□□□□□ (□□□-□□□ □□□□□□□□□□ □□□□, □□□ □□)	□□□□□□□□□□ □□□□ □□□□□□□ □□□□□□□□ □□□□ □□ □□□□ □□□□□ □□ □□ □□□□□□□□ □□□□□□□□ □□ □□□□□□ □□ □□□□□ □□□ □□ □□□□□ □□ □□ □□ □□ □□□□□□ □□□□□□□□ □□□ □□ □□□□□□□□□□ □ □□ □□□ — □□ □□□ □□□□□□ □□□□□□□□□□/□□□□□□□ □□□□□□□□□□ □□ □□□□ □□ □□□□ □□□□□□□□ □□□□□□ □□□ □□ □□□□□□ 8 □□□ □□□□ □□□ □□ □□□□ □□□□ □□□□□□ □□ □□□□□□ □□ □□□□□□□□ □□, □ □□ □□□□ □□□□□ □□□
P5P (pyridoxal-5-phosphate — the active form of vitamin B6, 20-50mg daily)	P5P is the required cofactor for glutamate decarboxylase (GAD), the enzyme that converts glutamate into GABA. Without adequate P5P, that conversion is less efficient, leaving relatively more glutamate and less of the inhibitory GABA counterbalance — directly relevant to the glutamate-heavy picture this section describes. Use the active P5P form rather than standard B6 (pyridoxine) if methylation is a concern, per the MTHFR row below.
'Brain Stack' — Uridine + DHA + CDP-Choline	□□□□ □□2 □□□□□□□□ □□□□□ □□ □□□□□□□□□ □□□□ □□— □□□□□□□□ □□□□□□ □□ □□□□□ □□□□□□□□□□ □□□□□, □ □□ □□□□ □□□□□ □□□□□
5-MTHF (□□□□□□□□□□ □□□□□)	Non-negotiable foundational methylation support, especially crucial if the MTHFR-linked depression/flatness pattern in Section 6 is applicable.
□□□□□□□□□□□□□□□ □□ □□□□□□□□□, □□□□□□□ □□□□□ □□□□ □□□□ □□ □□□ □□□□	Section 2 mein crash phase ko seedhe taur par support karta hai; binge ke baad sharir ki poshan ki kami asli hoti hai aur ise mansik lakshanon jitna hi gambhirta se lena chahiye.

⚠ □□□□□□□

On ketamine specifically, since it comes up naturally alongside glutamate: there is genuine research interest in ketamine for stimulant use disorder, working through NMDA-related synaptic plasticity rather than by 'reversing' toxicity directly, similar to its mechanism in treatment-resistant depression. It is Emerging-tier evidence, specialist-supervised only, and worth real caution rather than pursuit here specifically — the same Reward Deficiency Syndrome vulnerability discussed throughout Section 6 that made meth so compelling can make a second dissociative substance compelling too. Route of administration matters a real amount here: IV ketamine and esketamine (Spravato, intranasal, FDA-approved for treatment-resistant depression — an off-label use if applied to stimulant use disorder specifically) have far higher and more reliable bioavailability than oral ketamine, including troches — oral routes lose significant drug to first-pass liver metabolism, producing a less predictable effect. In this early, still-actively-repairing window, the more reliable IV or intranasal routes are generally considered the more clinically worthwhile option if this path is pursued at all; oral

ketamine is more commonly discussed as a later-stage option, closer to the one-year mark once the acute dopamine and glutamate repair work in Section 3 is substantially further along. This is a conversation for a psychiatrist familiar with stimulant use disorder aur ketamine ka research base, yeh khud se is stack mein add nahi karna hai.

Tier 2 — Medical and Psychiatric Support

- Methamphetamine withdrawal ke liye koi FDA-approved dawai nahi hai — benzo ya SSRI guides ke vipreet, yeh tier kisi pharmacological bridge ki jagah monitoring aur support par kendrit hai.
- Crash phase ke dauraan psychiatric evaluation karna uchit hai agar depression gambhir ho, khaaskar jab Din 1-5 mein asli suicide ka khatra hota hai — yeh koi atyaktar pratikriya nahi hai, balki ek dastavezi khatre ki avadhi par santulit pratikriya hai.
- If a prescriber introduces any medication (occasionally bupropion is used off-label for stimulant use disorder), disclose CYP2D6/CYP2B6 status if known, as per Section 6.

Tier 2.5 — '□□□ □□□□□□': □□□□□□□□□□□-□□□□□□□□□□ □□□□□□□ □□□□□□□□□

This deserves its own honest treatment rather than a single bullet, because it's a real approach that exists in specialist addiction medicine, and it's also genuinely easy to misunderstand as 'just get a prescription for the same kind of drug.' It is not that, when done correctly — but the distinction matters enough to walk through carefully.

⚠ □□□□□□□

Yeh koi self-directed strategy nahi hai. Iske liye ek psychiatrist ya addiction medicine specialist ki zaroorat hai jo actively decision manage kar raha ho, misuse ke risk ke liye monitor kar raha ho, aur ise time-limited clinical tool ki tarah treat kar raha ho—na ki koi open-ended replacement. Stimulant prescription ko informal tareeke se lena, ya kisi general prescriber se lena jise poori history ka pata na ho, neeche describe kiye gaye cheezon se materially alag aur bahut zyada risky hai.

The clinical logic: the Gray and Slow Return phases in Section 2 produce real, measurable executive-function impairment — attention, working memory, task initiation — that can closely resemble ADHD, whether or not ADHD was present before meth use began. In some specialist settings (this exists as documented practice in some countries' addiction medicine programs, sometimes called psychostimulant substitution or agonist-style stabilization), a carefully supervised, long-acting prescription stimulant — extended-release amphetamine salts (Adderall XR) or similar — is used short-term specifically to bridge that executive-function gap while the dopamine system in Section 3 does its slower underlying repair work, in the same structural spirit as using buprenorphine to stabilise an opioid-dependent system rather than letting it recover entirely unsupported.

What This Is	What This Isn't
A time-limited, specialist-supervised clinical	A green light to self-medicate the crash with

What This Is	What This Isn't
tool aimed at the specific executive-function gap in Section 2's Gray/Slow Return phases	any stimulant, prescribed or otherwise
Alongside, not instead of, the Tier 1 and Tier 3 work in this section	A substitute for the exercise, sleep, and neuroplasticity work that actually drives the DRD2 receptor recovery in Section 3
Evidence-limited aur aadi addiction medicine mein sachmuch bahas ka vishay hai — evidence tier: Emerging, na ki Established	□□ □□□□□□□, □□□□□-□□□□□□ □□□□ □□□□□□ - □□□□□□□ □□□□□ □□□□□□□□ □□□ □□ □□□ □□□□□□□ □□, □□ □□□□□□□ □□□□ □□□□□□ □□□□

□□□□□

Agar early recovery ka dhundhla aur flat feel karna aapko yeh sochne par majboor kar raha hai ki kya aapko sach mein ADHD hai, ya hamesha se tha — toh yeh ek jaayaz sawaal hai jo psychiatrist se poochne layak hai, na ki ise 'bas withdrawal ki baatein' maan kar taal dene wali baat. Kabhi-kabhi yeh withdrawal hota hai. Kabhi-kabhi koi asli, pehle se diagnose na hua ADHD hi woh cheez thi jiski wajah se stimulants itne aakarshak lage the, jaisa ki Section 6 ke phenotyping sawaalon mein bataya gaya hai. Ek specialist aapko sach mein yeh farq bata sakta hai, aur yahi baat 'ghost scaffolding' ka maqsad hai kholna, na ki usse badalna.

Tier 3 — □□□□□□□□ □□□□□ □□ □□□□□□□□□□□□□□□□□ □□□□□□ (□□□□□□ □□□□□)

- □□□□□□□ — □□ □□□□ □□□□□□□□□ □□□ □□□□ □□□□□□□□□□ □□□□□□□□□ □□□ BDNF, □□ □□□□ 2 □□ □□□□ 3 □□□ □□□□ □□□□□□□□□□ □□□□□□□ □□□□□□ □□ □□□ □□□□□□ □□□□□ □□, □□□□□ □□□ □□ □□□□□□□ □□□□□□□ □□ □□□□□□ □□ □□□□□□□ □□□□ □□□ □□□□□ □□□□□ □□□□□□□ □□□ □□ □□□□ □□, □□□□ □□□□, □□□ □□ □□□□□□□□□ □□□ □□, □□ □□□□□□□ □□□□□ □□□ 30-45 □□□□ □□ □□□□□ □□ □□□□ □□□□□□□ □□ □□ □□□□□
- □□□□ — 7-9 □□□□, □□□□□□ □□□ □□□□□; □□□□ □□ □□□□□ BDNF □□□□□□□□ □□ □□□□□□ □□□□□ □□□□□ □□□ □□ □□□□ □□□, □□□□□ □□□□ □□ □□ □□□□□□□ □□□□ □□□□ □□□ □□ □□□□ 3 □□□ □□□□□□ □□□□□□ □□□□□□□□□ □□ □□□□ □□ □□□□ □□□
- Subah ki dhoop — uthne ke baad pehle do ghante mein, ideal roop se, circadian alignment aur mood support ke liye 20+ minute bahar rehna.
- A novel, challenging learning activity—30+ minutes daily of something actively difficult (an instrument, a language, a complex skill)—drives neuroplasticity more than passive activities.
- Structured daily routine and environmental redesign — removing or altering triggers tied to use locations, people, and paraphernalia.

Section 9 — On Stigma

Methamphetamine carries a specific, heavier weight of social stigma than most other substances covered in this library — the 'tweaker' stereotype, assumptions

about criminality or moral failure, and a level of disgust in how the drug and its users get talked about publicly that alcohol or even opioid dependence often doesn't carry to the same degree. This is worth naming directly rather than leaving unspoken, because it has a real, documented practical effect: people with methamphetamine use disorder report — and research on healthcare-provider bias confirms — receiving measurably worse quality care, less thorough pain management, and more dismissive treatment than from medical providers than people with other substance use disorders, even when presenting with the same symptoms.

□□□□□

Agar aapko kabhi laga hai ki doctor, dentist, ya ER mein kuch batane se pehle khud ko taiyar karna padta hai, ya yeh samajhna padta hai ki kya ho sakta hai — toh woh ehsaas paranoia nahi hai. Yeh ek asli pattern ka sahi response hai. Iska matlab yeh nahi ki har provider aapke saath aisa hi vyavhaar karega, aur na hi iska matlab hai ki aap us jaankari ko chhipayein jo aapko surakshit rakhti hai (Section 0 aur Section 5 ke psychosis-risk overlap ke anusaar, aapki apni dekhbhaal ke liye ek sahi history zaroori hai) — lekin woh savdhani jo aap us baat-cheet mein le jaa rahe hain, woh kisi cheez ka atyaktar pratikriya nahi hai.

- If a provider's tone shifts noticeably once methamphetamine use is disclosed, that's worth naming directly to them ('I want to make sure this history doesn't change the quality of care I'm getting here') or, if that doesn't work, worth escalating to a different provider — you're allowed to do that.
- Addiction medicine specialists aur harm-reduction-oriented clinics mein aam taur par itna bias nahi hota jitna ki general practice ya emergency settings mein hota hai — jahan tak access milta hai, wahaan jaari dekhbhaal ke liye khaas taur par dhoondhna kaafi faydemand ho sakta hai.
- Stigma toh dawai ki reputation ke baare mein hai, aapke baare mein nahi. Section 3 mein bataya gaya dopamine system ka rebuild hone se koi matlab nahi rakhta ki log aapke character ke baare mein kya assume karte hain jab woh kaam kar raha hota hai.

Section 10 — Emergency Recognition, Restated

⚠ □□□□□□□□

□□□□□ 9152987821 □□ 112 □□ □□□ □□□□: □□□□□□□□□□ □□ □□□□□ □□ □□□ □□□□□□□□ □□□□□, □□□□ □□□ □□□□ □□ □□□□□□□ □□□ □□ □□□□, □□□□□ □□□ □□□□□□□ □□ □□□□□□□ □□ □□□□□ (□□□□□ □□ □□□□□, □□□ □□□ □□□□□□, □□□□□□□ □□□□□), □□□□□□□□□□ (□□□□□□□□□ □□□□, □□□□□□□□), □□ □□□□□□□ □□□□□□□□ □□□□ □□ □□□ □□□□□□□ □□□□□□ □□□□ □□□ □□□□ □□□□□ □□□□□□□ — □□□□, □□□□□□□□□, □□□□□, □□□□□, □□□□□□□□□□□□ □□□□ — □□ □□□ □□ □□□□□□ 2 □□ □□□□□□ □□□□□□□□ □□□, □□□□□ □□ □□□□□□ □□□□□□ □□, □□□ □□□□□ □□, □□ □□□ □□□ □□□□□□□□ □□ □□□□□□ □□□□□□□□□ □□□ □□ □□□□□□□ □□□

Section 11 — Full Protocol Cross-Reference Map

Reference	What It Offers Here
Recovery Kernel Meth/Stimulant Guide, Section 3 (The Detox Protocol)	The full source timeline this guide's Section 2 is built from, plus the complete supplement dosing and timing detail behind Section 8's Tier 1.
Recovery Kernel Compendium, Section 16.4 (Receptor Recovery — The Evidence)	The Volkow et al. and Heinz et al. citations behind Section 3's 12-17 month timeline, plus the comparative data for alcohol and cocaine receptor recovery.
Recovery Kernel Compendium, Protocol 01 (Shelter)	The crisis-stabilisation framework referenced throughout Section 2's crash and pit phases.
Recovery Kernel Compendium, Protocol 05 (Environmental Redesign)	Section 8, Tier 3 mein zikr kiye gaye trigger-removal aur environmental-modification ka kaam — istemaal se jude logon, jagahon, aur cheezon ko pehchaanna aur badalna.
Recovery Kernel Compendium, Protocol 06 (Daily Structure)	The consistent-routine framework appropriate starting around the Weeks 2-4 mark in Section 2, once the acute crash has passed.
Recovery Kernel Compendium, Protocol 20 (Identity Reconstruction) and C-28 ('The Recast')	Appropriate starting around Months 1-3 in Section 2 — not earlier. Building an identity and a set of genuine, high-intensity outlets suited to the Warrior COMT profile in Section 6, rather than one organised around either the drug or its absence.
Recovery Kernel Compendium, Section 16 (Neuroplasticity Architecture)	Section 3 mein zikr kiya gaya poora 90-din ka rebuilding framework — vyayam, neend, seekhne aur dhoop ke protocol poore vivaran ke saath, jismein Section 8 ki Tier 3 ke peeche ka saptahik structure bhi shaamil hai.
Recovery Kernel Chemsex Guide	If methamphetamine use occurred in a chemsex context specifically — the combined GHB/meth/mephedrone recovery timeline and unified supplement stack address the multi-substance picture this guide covers only for meth alone.
Recovery Kernel Complex Trauma and the Substance Connection	□□ □□□□ □□ □□□□ □□□□□□ 3 (□□□□□□-□□□□□□ □□-□□□□) □□ □□□□□□: □□□□□□□ □□□□□□□□□□□□□ □□ □□□□ □□□□□□□ □□□ □□□□□ □□ □□□□□□□□ □□□□□□-□□□□□□□ □□□□□ □□ □□ □□□□□ □□□ □□ □□□□□□□ □□□□□ □□ □□ □□ □□□□ □□ — □□□ □□ □□□□□□ □□□□ □□□□ □□ □□ □□ □□□□ □□ □□□ □□□□ □□□□□□ □□□□□

Section 12 — Closing

□ □□□□□

□□□□□ □□□□□□□ □□□□ □□□□□□□□□□□□□□ □□ □□□□□□ □□□□ □□ □□ □□□□□□ □□□ □□ □□□□ □□□ □□□□ □□□ □□□□ □□□□□□□ □□ □□□□□□□□ □□: □□□□□□ □□ □□□□ □□□□□ □□□□□ □□□□□□, □□ □□□ □□ □□□□ □□□ □□ □□□□ □□□□□□□□□□ □□□□□□□□□□ □□□□□□, □□ □□ 90-□□□ □□ □□□□□□ □□□□ □□□□□□□□ □□□□□□□, □□□□ □□ □□□ □□□□□□ □□□□ □□□□ □□ □□□□□ □□ □□□□ □□□□ □□□□□□□□□□□□ □□□□□ □□ □□□□ □□□□ □□□ □□□□□ □□ □□□ □□□ □□ □□□□□ □□□□ □□ □□ □□□ □□□ □□ □□□ □□□ □□ □□, □□ □□□ □□ □□, □□ □□□ □□ □□□□□ □□ □□□□□□ □□□□ □□ □□□□ □□ □□□□ □□□

END OF GUIDE — DISCONTINUANCE PROTOCOL: METHAMPHETAMINE

Harm Reduction Resource — Not Medical Advice — Not a Substitute for Emergency Care

Crisis Resources: 988 (Suicide & Crisis Lifeline, call or text) | Crisis Text: HOME to 741741 | SAMHSA: 1-800-662-4357